Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 148

1.

Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.

Monsees GM, Malone KE, Tang MT, Newcomb PA, Li CI.

J Natl Cancer Inst. 2011 Dec 7;103(23):1752-60. doi: 10.1093/jnci/djr399. Epub 2011 Oct 21.

PMID:
22021667
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Second primary breast cancer occurrence according to hormone receptor status.

Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA.

J Natl Cancer Inst. 2009 Aug 5;101(15):1058-65. doi: 10.1093/jnci/djp181. Epub 2009 Jul 9.

PMID:
19590058
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.

Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholz B, Thomas DC, Begg CB, Capanu M, Ejlertsen B, Stovall M, Boice JD Jr, Shore RE; Women's Environment, Cancer and Radiation Epidemiology Study Collaborative Group, Bernstein JL.

J Natl Cancer Inst. 2008 Jan 2;100(1):32-40. Epub 2007 Dec 25.

PMID:
18159070
[PubMed - indexed for MEDLINE]
Free Article
4.

Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients.

Bedrosian I, Hu CY, Chang GJ.

J Natl Cancer Inst. 2010 Mar 17;102(6):401-9. doi: 10.1093/jnci/djq018. Epub 2010 Feb 25.

PMID:
20185801
[PubMed - indexed for MEDLINE]
Free Article
5.

Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.

Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N.

J Natl Cancer Inst. 2004 Apr 7;96(7):516-23.

PMID:
15069113
[PubMed - indexed for MEDLINE]
Free Article
6.

Predicting risk of breast cancer in postmenopausal women by hormone receptor status.

Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA; Women's Health Initiative Investigators.

J Natl Cancer Inst. 2007 Nov 21;99(22):1695-705. Epub 2007 Nov 13.

PMID:
18000216
[PubMed - indexed for MEDLINE]
Free Article
7.

Lifetime recreational exercise activity and breast cancer risk among black women and white women.

Bernstein L, Patel AV, Ursin G, Sullivan-Halley J, Press MF, Deapen D, Berlin JA, Daling JR, McDonald JA, Norman SA, Malone KE, Strom BL, Liff J, Folger SG, Simon MS, Burkman RT, Marchbanks PA, Weiss LK, Spirtas R.

J Natl Cancer Inst. 2005 Nov 16;97(22):1671-9.

PMID:
16288120
[PubMed - indexed for MEDLINE]
Free Article
8.

Oral bisphosphonate use and breast cancer incidence in postmenopausal women.

Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB.

J Clin Oncol. 2010 Aug 1;28(22):3582-90. doi: 10.1200/JCO.2010.28.2095. Epub 2010 Jun 21.

PMID:
20567009
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Relationship between diabetes and risk of second primary contralateral breast cancer.

Li CI, Daling JR, Tang MT, Malone KE.

Breast Cancer Res Treat. 2011 Jan;125(2):545-51. doi: 10.1007/s10549-010-1035-4. Epub 2010 Jul 13.

PMID:
20625814
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.

Milne RL, Benítez J, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Arias JI, Zamora MP, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schürmann P, Bremer M, Hillemanns P, Dörk T, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Hall P, Czene K, Liu J, Li Y, Ahmed S, Dunning AM, Maranian M, Pharoah PD, Chenevix-Trench G, Beesley J; kConFab Investigators; AOCS Group, Bogdanova NV, Antonenkova NN, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch H, Justenhoven C, Ko YD, Haas S, Fasching PA, Strick R, Ekici AB, Beckmann MW, Giles GG, Severi G, Baglietto L, English DR, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Turnbull C, Hines S, Renwick A, Rahman N, Nordestgaard BG, Bojesen SE, Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa A, Kataja V, Kosma VM, García-Closas M, Chanock S, Lissowska J, Brinton LA, Chang-Claude J, Wang-Gohrke S, Shen CY, Wang HC, Yu JC, Chen ST, Bermisheva M, Nikolaeva T, Khusnutdinova E, Humphreys MK, Morrison J, Platte R, Easton DF; Breast Cancer Association Consortium.

J Natl Cancer Inst. 2009 Jul 15;101(14):1012-8. doi: 10.1093/jnci/djp167. Epub 2009 Jun 30.

PMID:
19567422
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.

Nichols HB, Berrington de González A, Lacey JV Jr, Rosenberg PS, Anderson WF.

J Clin Oncol. 2011 Apr 20;29(12):1564-9. doi: 10.1200/JCO.2010.32.7395. Epub 2011 Mar 14.

PMID:
21402610
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer.

Li CI, Daling JR, Porter PL, Tang MT, Malone KE.

J Clin Oncol. 2009 Nov 10;27(32):5312-8. doi: 10.1200/JCO.2009.23.1597. Epub 2009 Sep 8.

PMID:
19738113
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M.

J Natl Cancer Inst. 2007 Feb 21;99(4):283-90.

PMID:
17312305
[PubMed - indexed for MEDLINE]
Free Article
14.

Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.

Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP.

J Natl Cancer Inst. 2003 Oct 1;95(19):1467-76.

PMID:
14519753
[PubMed - indexed for MEDLINE]
Free Article
15.

Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study.

Li CI, Chlebowski RT, Freiberg M, Johnson KC, Kuller L, Lane D, Lessin L, O'Sullivan MJ, Wactawski-Wende J, Yasmeen S, Prentice R.

J Natl Cancer Inst. 2010 Sep 22;102(18):1422-31. doi: 10.1093/jnci/djq316. Epub 2010 Aug 23.

PMID:
20733117
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Bisphosphonates: beyond prevention of bone metastases.

Rennert G.

J Natl Cancer Inst. 2011 Dec 7;103(23):1728-9. doi: 10.1093/jnci/djr441. Epub 2011 Oct 21. No abstract available.

PMID:
22021669
[PubMed - indexed for MEDLINE]
Free Article
17.

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sørensen HT, Hellberg Y, Christensen M, Pedersen L, Hamilton-Dutoit S.

J Natl Cancer Inst. 2011 Mar 16;103(6):489-500. doi: 10.1093/jnci/djr010. Epub 2011 Feb 15.

PMID:
21325141
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.

Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE.

J Natl Cancer Inst. 2005 Apr 20;97(8):595-602.

PMID:
15840882
[PubMed - indexed for MEDLINE]
Free Article
19.

Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature.

Liu Y, Zhao S, Chen W, Hu F, Zhu L, Zhang Q, Zhao Y.

Clin Breast Cancer. 2012 Aug;12(4):276-81. doi: 10.1016/j.clbc.2012.04.003. Epub 2012 May 22. Review.

PMID:
22622199
[PubMed - indexed for MEDLINE]
20.

Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer.

Li CI, Malone KE, Weiss NS, Daling JR.

J Natl Cancer Inst. 2001 Jul 4;93(13):1008-13.

PMID:
11438566
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk